Treating cancer cachexia to treat cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Skeletal muscle wasting is a major component of cachectic states found in a variety of disease settings, including cancer. As increasing caloric intake often provides little benefit in combating muscle loss in cachectic patients, a major research focus has been to develop strategies stimulating muscle anabolic pathways - in an attempt to fight the catabolic pathways induced during cachexia. Two recent papers have reported the beneficial effects of blocking the myostatin/activin signalling pathway in mouse models of cancer cachexia. We discuss the implications of their findings both with respect to the role that this signalling pathway may play in the aetiology of cachexia and with respect to the prospects for targeting this pathway as a therapeutic strategy in patients with cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“Mutations in the Mstn gene have been shown to result in dramatic increases in muscle mass in multiple species [5-11], and inhibitors of MSTN signalling have been shown to cause increases in muscle growth when administered”
BackgroundSelf-citationRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Self-citationA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556 · cited 1×
“Mutations in the Mstn gene have been shown to result in dramatic increases in muscle mass in multiple species [5-11], and inhibitors of MSTN signalling have been shown to cause increases in muscle growth when administered”
BackgroundMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Mutations in myostatin ( GDF8 ) in Double-Muscled Belgian Blue and Piedmontese Cattle
Kambadur, R., Sharma, M., Smith, T. P. L., & Bass, J. J. (1997) · Genome Research · doi:10.1101/gr.7.9.910 · Cited by 1,204 · cited 1×
“Mutations in the Mstn gene have been shown to result in dramatic increases in muscle mass in multiple species [5-11], and inhibitors of MSTN signalling have been shown to cause increases in muscle growth when administered”
BackgroundFunctional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“systemically to adult mice [12-15].”
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826 · cited 1×
“Mutations in the Mstn gene have been shown to result in dramatic increases in muscle mass in multiple species [5-11], and inhibitors of MSTN signalling have been shown to cause increases in muscle growth when administered”
BackgroundREGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819 · cited 1×
“Discussion Myostatin (MSTN) is a transforming growth factor-b (TGF-b) family member that normally acts to limit muscle mass (for review, see [4]).”
BackgroundSelf-citationMyostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Self-citationActivation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
Wolfman, N. M., McPherron, A. C., Pappano, W. N., Davies, M. V., Song, K., Tomkinson, K. N., Wright, J. F., Zhao, L., Sebald, S. M., Greenspan, D. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534946100 · Cited by 454
Self-citationSignaling pathways perturbing muscle mass.
Glass, D. J. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833862df · Cited by 359 · cited 1×
“Loss of muscle mass can result either from primary muscle degenerative diseases, such as the muscular dystrophies, or as a secondary consequence of cachectic disease processes also affecting other tissues, such as cancer, burns, renal failure, sepsis and congestive heart failure (for review, see [1]).”
BackgroundSelf-citationGilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K., & Thissen, J.-P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2009 · Cited by 248 · cited 1×
“Previous studies had shown that several TGF-b family members, including activins, are as active as MSTN in inhibiting myoblast differentiation, acting through the ActRIIB pathway [21], and that electroporation of an activin A expression cassette directly into muscle can induce myofiber atrophy [22], suggesting that ac…”
BackgroundGenetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238 · cited 1×
“Importantly, mice carrying a heart-specific knockout of the Mstn gene appear to be resistant to skeletal muscle loss following transverse aortic constriction [30].”
BackgroundMyostatin activation in patients with advanced heart failure and after mechanical unloading
George, I., Bish, L. T., Kamalakkannan, G., Petrilli, C. M., Oz, M. C., Naka, Y., Lee Sweeney, H., & Maybaum, S. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq039 · Cited by 136
Cited by
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L., Koniaris, L. G., & Zimmers, T. A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2012 · Cited by 463
Molecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
“Furthermore, mice with a heart-specific knockout of the myostatin gene appear to be resistant to skeletal muscle loss, which indicates that targeting this pathway could be of benefit for patients with muscle wasting in the context of chronic heart failure and maybe also in cancer cachexia [183, 184].”
BackgroundPerakakis, N., Mougios, V., Fatouros, I., Siopi, A., Draganidis, D., Peradze, N., Ghaly, W., & Mantzoros, C. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01056 · Cited by 52
Metadata
- Authors
- Lee, S.-J., & Glass, D. J.
- Venue
- Skeletal Muscle
- Published
- 2011
- Volume
- 1
- Issue
- 1
- Pages
- 2
- ISSN
- 2044-5040 (ISSN-L)
- OpenAlex
- W2143888267
- Cited by
- 50
- References
- 16
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.